Gilead Sciences, Inc. (GILD) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Gilead Sciences financial statements at a glance

Gilead Sciences reported revenue of $29.44 billion for fiscal year 2025 (ended December 31, 2025), up 2.4% from fiscal year 2024. Net income was $8.51 billion, a net margin of 28.9%, and diluted earnings per share were $6.78.

At the end of fiscal year 2025 it had total assets of $59.02 billion, total liabilities of $36.41 billion and shareholders' equity of $22.70 billion, with cash and short-term investments of $9.61 billion and total debt of $24.94 billion.

Its operations brought in $10.02 billion of cash; capital spending was $563.00 million, leaving free cash flow of $9.46 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

GILD logo

Gilead Sciences, Inc.

GILDUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
29.44B
Prev Year: 28.75B
YoY: +2.4%
Operating Revenue
29.44B
Prev Year: 28.75B
YoY: +2.4%
Total Unusual Items Excluding Goodwill
-1.23B
Prev Year: -9.12B
YoY: +86.5%
Total Unusual Items
-1.23B
Prev Year: -9.12B
YoY: +86.5%
Normalized EBITDA
14.81B
Prev Year: 13.55B
YoY: +9.3%
Tax Rate for Calcs
0.131
Prev Year: 0
Tax Effect of Unusual Items
-161.34M
Prev Year: -2.78B
YoY: +94.2%
Total Operating Income as Reported
10.02B
Prev Year: 1.66B
YoY: +503.0%
Write-offs
590.00M
Prev Year: 4.18B
YoY: -85.9%
Selling and Marketing Expense
3.52B
Cost of Revenue
6.23B
Prev Year: 6.25B
YoY: -0.3%
Gross Profit
23.21B
Prev Year: 22.50B
YoY: +3.1%
Operating Expense
11.51B
Prev Year: 12.00B
YoY: -4.1%
Selling General and Administrative
5.71B
Prev Year: 6.09B
YoY: -6.3%
General and Administrative Expense
2.19B
Other General and Administrative
2.19B
Research and Development
5.80B
Prev Year: 5.91B
YoY: -1.8%
Operating Income
11.70B
Prev Year: 10.51B
YoY: +11.4%
Net Non Operating Interest Income Expense
-675.00M
Prev Year: -696.00M
YoY: +3.0%
Non-operating Interest Income
349.00M
Prev Year: 281.00M
YoY: +24.2%
Non-operating Interest Expense
1.02B
Prev Year: 977.00M
YoY: +4.8%
Other Income Expense
-1.23B
Prev Year: -9.12B
YoY: +86.5%
Gain on Sale of Securities
451.00M
Prev Year: -274.00M
YoY: +264.6%
Special Income Charges
-1.68B
Prev Year: -8.84B
YoY: +81.0%
Restructuring and Mergers Acquisition
66.00M
Other Special Charges
1.02B
Prev Year: 4.66B
YoY: -78.0%
Other Non-operating Income (expense)
-1.00M
Prev Year: -2.00M
YoY: +50.0%
Pre-tax Income
9.80B
Prev Year: 690.00M
YoY: +1319.7%
Provision for Income Taxes
1.29B
Prev Year: 211.00M
YoY: +509.5%
Net Income Common Stockholders
8.51B
Prev Year: 480.00M
YoY: +1672.9%
Net Income
8.51B
Prev Year: 480.00M
YoY: +1672.9%
Net Income Including Non-Controlling Interests
8.51B
Prev Year: 480.00M
YoY: +1672.9%
Net Income from Continuing Operations
8.51B
Prev Year: 479.00M
YoY: +1676.6%
Diluted NI Available to Com Stockholders
8.51B
Prev Year: 480.00M
YoY: +1672.9%
Basic EPS
6.84
Prev Year: 0.38
YoY: +1700.0%
Diluted EPS
6.78
Prev Year: 0.38
YoY: +1684.2%
Weighted Average Shares (basic)
1.24B
Prev Year: 1.25B
YoY: -0.2%
Weighted Average Shares (diluted)
1.25B
Prev Year: 1.25B
YoY: 0.0%
Total Expenses
17.74B
Prev Year: 18.25B
YoY: -2.8%
Net Income from Continuing and Discontinued Operation
8.51B
Prev Year: 480.00M
YoY: +1672.9%
Normalized Income
9.58B
Prev Year: 6.82B
YoY: +40.5%
Interest Income
349.00M
Prev Year: 281.00M
YoY: +24.2%
Interest Expense
1.02B
Prev Year: 977.00M
YoY: +4.8%
Net Interest Income
-675.00M
Prev Year: -696.00M
YoY: +3.0%
EBIT
10.82B
Prev Year: 1.67B
YoY: +549.1%
EBITDA
13.58B
Prev Year: 4.43B
YoY: +206.3%
Reconciled Cost of Revenue
6.23B
Prev Year: 6.25B
YoY: -0.3%
Reconciled Depreciation
2.76B
Prev Year: 2.77B
YoY: -0.3%
Net Income from Continuing Operation Net Minority Interest
8.51B
Prev Year: 480.00M
YoY: +1672.9%
Values in USD

Gilead Sciences key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$29.4B$28.8B$27.1B$27.3B$27.3B
Gross profit$23.2B$22.5B$20.6B$21.6B$20.7B
Operating income$11.7B$10.5B$8.8B$11.0B$10.9B
Net income$8.5B$480.0M$5.7B$4.6B$6.2B
Diluted EPS$6.78$0.38$4.50$3.64$4.93
Total assets$59.0B$59.0B$62.1B$63.2B$68.0B
Total liabilities$36.4B$39.7B$39.4B$42.0B$46.9B
Shareholders' equity$22.7B$19.3B$22.8B$21.2B$21.1B
Cash and short-term investments$9.6B$11.6B$7.3B$6.4B$6.5B
Total debt$24.9B$26.7B$25.0B$25.2B$26.7B
Operating cash flow$10.0B$10.8B$8.0B$9.1B$11.4B
Capital spending$563.0M$523.0M$585.0M$728.0M$579.0M
Free cash flow$9.5B$10.3B$7.4B$8.3B$10.8B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Gilead Sciences's revenue in fiscal year 2025?

$29.44 billion, up 2.4% from $28.75 billion in fiscal year 2024.

How much profit does Gilead Sciences make?

Gilead Sciences reported net income of $8.51 billion for fiscal year 2025 (28.9% of revenue); operating income was $11.70 billion.

How much cash and debt does Gilead Sciences have?

At the end of fiscal year 2025: cash and short-term investments of $9.61 billion and total debt of $24.94 billion.

What is Gilead Sciences's free cash flow?

$9.46 billion in fiscal year 2025 (operating cash flow of $10.02 billion minus capital spending of $563.00 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube